• Troglitazone and the PPARγ–TAM Translation Gap

  2026-08-12

  Troglitazone offers a mechanistically interesting bridge between PPAR-driven metabolic biology and tumor-associated macrophage research. This article positions it as a hypothesis-generating PPARγ agonist for testing SPP1-linked myeloid states, while separating product attributes, anchor-study evidence, and translational limitations.

• Arachidonic Acid Accelerates Vaccine Humoral Immunity

  2026-08-12

  The reference study identifies dietary arachidonic acid as a potential immunological adjuvant that accelerates rabies vaccine-induced neutralizing antibody responses in mice and human volunteers. Its mechanistic contribution is the connection between arachidonic acid enrichment in lymph nodes, prostaglandin I2 signaling, CD86 expression, and activation-induced cytidine deaminase in B cells.

• NIAGEN in iPSC-RGC Assay Design

  2026-08-11

  Nicotinamide Riboside Chloride (NIAGEN) can help researchers test how NAD+ availability influences energy homeostasis in stem cell-derived retinal ganglion cell models. This article focuses on assay architecture, reproducibility, and the boundaries between differentiation biology and neuroprotection.

• Verapamil HCl: Calcium Flux, Efflux, Cell Fate

  2026-08-11

  Verapamil HCl is an L-type calcium channel blocker whose experimental effects may reflect both calcium signaling and drug-efflux control. This guide explains how to distinguish those mechanisms in myeloma, apoptosis, and collagen-induced arthritis studies.

• Baicalein Workflows for Apoptosis Research

  2026-08-10

  Baicalein provides a practical chemical perturbation tool for connecting 12-LOX activity with apoptosis, inflammatory signaling, and cancer-cell phenotypes. This workflow emphasizes solvent control, orthogonal readouts, and a paired neuronal–tumor assay strategy inspired by recent chemotherapy-neurotoxicity research.

• In Vitro Drug Response: Viability, Growth, and Death

  2026-08-09

  Hannah R. Schwartz’s dissertation distinguishes drug-induced growth inhibition from actual cell killing, showing that relative viability and fractional viability capture different dimensions of an in vitro cancer response. This framework can improve interpretation of drug screens, particularly when cell-cycle arrest and delayed death occur together.

• MVC Entry via RhoA/ROCK1 Tight-Junction Signaling

  2026-08-08

  Ren and colleagues show that Minute Virus of Canines (MVC) uses a host RhoA/ROCK1/MLC2 signaling axis to remodel tight junctions and expose occludin for VP2-mediated infection. The study connects a direct VP2–ROCK1 interaction with cytoskeletal contraction, barrier permeability, and reduced infection after pharmacologic pathway inhibition.

• Mavorixafor Hydrochloride: Assay Logic

  2026-08-07

  AMD-070 hydrochloride is a CXCR4 antagonist for dissecting chemokine-directed migration and immune-cell phenotypes. This article uses a tissue-perfusion study to show how endpoint selection, controls, and cross-domain limits can improve translational assay design.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-08-07

  Anlotinib hydrochloride delivers potent, multi-pathway anti-angiogenic effects that outperform established TKIs in functional cancer research models. This guide translates reference-backed methods into practical protocols, troubleshooting, and comparative insights for advanced tumor angiogenesis assays.

• Cy3-UTP: Advanced RNA Labeling for Imaging and Interaction A

  2026-08-06

  Cy3-UTP empowers researchers with high-brightness, photostable RNA labeling, enabling precise fluorescence imaging and robust RNA-protein interaction studies. Its seamless integration into in vitro transcription workflows sets a new benchmark for sensitivity and specificity in RNA detection assays.

• Vasopressin Analogues: Expanding Roles of Lypressin Acetate

  2026-08-06

  The reference study provides a comprehensive review of vasopressin and its analogues, highlighting their evolution from natural hormones to multifunctional therapeutics. Notably, it details lypressin acetate’s utility in diabetes insipidus and explores its emerging antiviral potential, offering guidance for researchers on peptide-based drug development.

• Practical Guidance for 740 Y-P: PI 3-Kinase Activator Workfl

  2026-08-05

  740 Y-P enables controlled activation of the PI3K/AKT pathway for researchers studying vesicular trafficking, neuronal cell survival, and apoptosis mechanisms. Its use is recommended for in vitro biochemical and cellular assays—not for animal or clinical applications—where selective pathway modulation is required. This guide covers technical setup, parameter selection, and troubleshooting for effective application.

• Distinct Vascular Effects of JAK Inhibitors in Endothelial I

  2026-08-05

  This study systematically compares the vascular impacts of multiple JAK inhibitors—including tofacitinib citrate—on endothelial cells under inflammatory cytokine challenge. The findings reveal nuanced anti-inflammatory actions but also highlight procoagulant risks and cytotoxicity with certain inhibitors, refining their application in immune regulation and inflammatory disorder research.

• Stable Yeast-Based Exendin-4 Expression for Accessible Diabe

  2026-08-04

  This paper demonstrates a stable system for expressing Exendin-4 in Saccharomyces cerevisiae, offering a cost-effective and scalable platform for producing GLP-1 receptor agonists for type 2 diabetes research and therapeutics. The work establishes foundational protocols and verifies the biological relevance of yeast-expressed Exendin-4, enabling new avenues for affordable insulin sensitivity and beta cell function studies.

• L-Alanyl-L-Glutamine (B8228): Protocol and GI Research Use

  2026-08-04

  L-Alanyl-L-Glutamine is a stable, water-soluble dipeptide designed to enhance intestinal mucosa protection and intestinal barrier function in nutritional and GI research models. It is best suited for workflows requiring robust antioxidant system support and precise control of inflammation attenuation during catabolic stress. This product should not be used outside established gastrointestinal or nutritional supplement applications, and long-term solution storage is discouraged.

551 records 8/37 page Previous Next First page 上5页 678910 下5页 Last page